Antibiogram pattern in extended spectrum beta lactamase nano enzyme producing gram negative bacilli in Iranian urinary tract infection

Urinary tract infection is one of the most prevalent infections worldwide. Extended spectrum beta lactamase (ESBL) is defined as beta lactamase capable of hydrolyzing third generation cephalosporin's, and is inhibited by beta lactamase inhibitor. Escherichia coli and Klebsiella pneumoniae are relevant opportunistic pathogens that account for nosocomial infections. Antibiotics resistance in extended spectrum beta lactamase producer strain is currently one of the emerging health related problems in the world. The present study was performed in two tertiary care hospitals in Iran during a 14 month period. Standard microbiological methods were performed. In order to validate the extended-spectrum beta-lactamases producing strains, ceftazidim, ceftazidimclavulanic acid, cefotaxim, and cefotaximclavulanic acid were used, by disk diffusion method. Frequency of ESBLs in E. coli and K. pneumoniae strains was 35.06 and 35.71%, respectively. According to antibiogram result respectively 59.2, 54.9, 30.3, 27.8, 19.5 and 16.7% of E. coli strains were resistant to co-trimoxazole, nalidixic acid, ciprofloxacin, gentamicin, ceftazidime and nitrofurantoin, and respectively 75, 50, 40, 44.5, 37.5, 37.5, 22.3 and 0% of K. pneumoniae strains were resistant to ampicillin, co-trimoxazole, nitrofurantoin, ceftazidime, amikacin, cephotaxime, imipenem and ciprofloxacin. Justifiable

Escherichia coli, Klebsiella pneumoniae, urinary tract infection, extended spectrum beta lactamase.